SPOTLIGHT: Merck KGaA leads team to sell Erbitux in Japan

Merck KGaA leads team to sell Erbitux in Japan
Call it a trifecta: ImClone Systems, Bristol-Myers Squibb and Merck KGaA are joining together to develop and market ImClone's cancer drug Erbitux in Japan, with Merck getting half the proceeds. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.